Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul:79:1-14.
doi: 10.1016/j.ejca.2017.03.030. Epub 2017 Apr 26.

The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer

Jacopo Desiderio  1 , Joseph Chao  2 , Laleh Melstrom  3 , Susanne Warner  3 , Federico Tozzi  3 , Yuman Fong  3 , Amilcare Parisi  4 , Yanghee Woo  5
Affiliations
Review

The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer

Jacopo Desiderio et al. Eur J Cancer. 2017 Jul.

Abstract

Importance: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used within various multimodality strategies for the prevention and treatment of gastric cancer peritoneal carcinomatosis.

Objective: To systematically evaluate the role of HIPEC in gastric cancer and clarify its effectiveness at different stages of peritoneal disease progression.

Data sources: Medline and Embase databases between January 1, 1985 and June 1, 2016.

Study selection: Randomised control trials and high-quality non-randomised control trials selected on a validated tool (methodological index for non-randomised studies) comparing HIPEC and standard oncological management for the treatment of advanced stage gastric cancer with and without peritoneal carcinomatosis were considered.

Data extraction and synthesis: A random-effects network meta-analysis.

Main outcomes and measures: The primary outcomes were overall survival and disease recurrence. Secondary outcomes were overall complications, type of complications, and sites of recurrence.

Results: A total of 11 RCTs and 21 non-randomised control trials (2520 patients) were included. For patients without the presence of peritoneal carcinomatosis (PC), the overall survival rates between the HIPEC and control groups at 3 or 5 years resulted in favour of the HIPEC group (risk ratio [RR] = 0.82, P = 0.01). No difference in the 3-year overall survival (RR = 0.99, P = 0.85) in but a prolonged median survival of 4 months in favour of the HIPEC group (WMD = 4.04, P < 0.001) was seen in patients with PC. HIPEC was associated with significantly higher risk of complications for both patients with PC (RR = 2.15, P < 0.01) and without (RR = 2.17, P < 0.01). This increased risk in the HIPEC group was related to systemic drugs toxicity. Anastomotic leakage rates were found to be similar between groups.

Conclusions: Our study demonstrates a survival advantage of the use of HIPEC as a prophylactic strategy and suggests that patients whose disease burden is limited to positive cytology and limited nodal involvement may benefit the most from HIPEC. For patients with extensive carcinomatosis, the completeness of cytoreductive surgery is a critical prognostic factor for survival. Future RCTs should better define patient selection criteria.

Keywords: Gastric cancer; HIPEC; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the records selection process.
Figure 2
Figure 2
Quality Assessment of Randomized Controlled Studies based on the Cochrane Risk of Bias Tool.
Figure 3
Figure 3
AGC without carcinomatosis - overall survival at different endpoints. 1 year (A), 3 years (B), and 5 years (C) follow-up.
Figure 4
Figure 4
GCPC - overall survival at different endpoints. 1 year (A), 2 years (B), and 3 years (C) follow-up.
See this image and copyright information in PMC

References

    1. G Estimated cancer incidence, mortality and prevalence worldwide. 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; accessed August 10th, 2016.
    1. Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, et al. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22(3):1139–59. - PMC - PubMed
    1. Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;2014:912418. - PMC - PubMed
    1. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. - PubMed
    1. Deraco M, Kusamura S, Virzi S, Puccio F, Macri A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20. - PubMed

MeSH terms

Substances